about
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cellsElevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesion.A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease.Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells.Epigenetic distortion to VDR transcriptional regulation in prostate cancer cells.Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns.11β-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.Cellular and genetic models of H6PDH and 11β-HSD1 function in skeletal muscle.Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism.11β-HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice.Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.TNFα-mediated Hsd11b1 binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle.Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells.Glucocorticoids Reprogram β-Cell Signaling to Preserve Insulin Secretion.PARP Inhibitors: Staying on Target?Metabolic tracing reveals novel adaptations to skeletal muscle cell energy production pathways in response to NAD+ depletionNicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical CarcinomaMetabolic tracing reveals novel adaptations to skeletal muscle cell energy production pathways in response to NAD + depletionNicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy
P50
Q33563699-BA84D28B-E425-490F-A2CC-9EC64EE52D9DQ34094960-4F45777A-F44F-420F-A120-25A2BB1F9291Q34169832-F878276D-7F56-424E-9F28-7C3CA4642E5AQ34723871-A2007789-7C70-4923-86B6-204AF726CB9EQ35600481-1540E889-1E6D-4346-A831-5ED647C06841Q36587617-1ED8B3AC-EA29-4BEA-8D79-7A06DED96E36Q37417655-16176C84-6F89-47D2-9788-D4CCE584DEBDQ38658108-241929E5-DFCA-49D6-A48C-ADD3522F93D1Q38780542-0995599A-FB78-4B2B-A654-38333B3DAB17Q38860951-288A9269-7112-4C56-951A-EE479617EBB3Q39626951-BDD9A743-27E2-4E6F-ADCC-D2833EA89435Q39766222-7703DB1F-445F-43B8-991C-17205DA21101Q41068775-361F4AED-D208-49AE-B3D7-5B5EF81DB5AAQ48184307-04C6F2D5-3745-46CE-9800-F8167F145FA5Q51240194-C34F557E-03E9-4D6F-B4CF-C30DD08075C9Q60056626-41DB0CED-D556-4E44-8B96-3432FE5EFB35Q61958115-08F43DE5-BF8A-4083-A3F7-6A5F8255A4E4Q90872811-0C463175-334C-45A4-B43D-76EBFCD84D7FQ92617562-C72DBCD5-7A44-455E-94B3-E6AD7866C6E6Q92665487-E0A9D60D-6045-429A-B4D7-82B615FB66B5
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Craig L Doig
@ast
Craig L Doig
@en
Craig L Doig
@en-gb
Craig L Doig
@es
Craig L Doig
@nl
Craig L Doig
@sl
type
label
Craig L Doig
@ast
Craig L Doig
@en
Craig L Doig
@en-gb
Craig L Doig
@es
Craig L Doig
@nl
Craig L Doig
@sl
prefLabel
Craig L Doig
@ast
Craig L Doig
@en
Craig L Doig
@en-gb
Craig L Doig
@es
Craig L Doig
@nl
Craig L Doig
@sl
P106
P21
P31
P496
0000-0001-9694-4230